Helicobacter pylori (H. pylori) is a prevalent, worldwide, chronic infection. Choice of
treatment can be modified according to antibiotic-resistance rates of H. pylori. The ideal …

Triple therapy, consisting of two antibiotics, clarithomycin and amoxicillin or metronidazole in
combination with a proton pump inhibitor (PPI) has become the first-line option for infection …

Although Helicobacter pylori infection is both a common and a serious bacterial infection,
antimicrobial therapies have rarely been optimized, are prescribed empirically, and provide …

This paper reviews the literature about first‐line therapies for H. pylori infection in recent
years. First‐line therapies are facing a challenge because of increasing treatment failure …

Helicobacter pylori (H. pylori) is an important major cause of peptic ulcer disease and gastric
malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric …

Helicobacter pylori infection still represents a major health issue, especially in developing
countries, with an estimate of 4 billion of infected subjects in 2015. The increase of antibiotic …

Helicobacter pylori continues to present therapeutic challenges for clinicians across the
world. This review article aims to consolidate current knowledge of H. pylori infection with a …

Helicobacter pylori infection can lead to gastritis, gastric and duodenal ulcers, and gastric
cancer. Consequently, complete eradication is the goal of therapy. First‐line therapy for H …

Helicobacter pylori (H. pylori) infection is highly associated with the occurrence of
gastrointestinal diseases, including gastric inflammation, peptic ulcer, gastric cancer, and …

Background Helicobacter pylori infection is still frequent in the community and all infected
subjects should be offered an eradication therapy. Nowadays physicians have to face the …